Cullinan Therapeutics, Inc. (CGEM) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
One Main Street
Cambridge, MA 02142
United States of America (the)
Phone
617 410 4650
Sector
Healthcare
Industry
Biotechnology
Employees
109
First IPO Date
January 08, 2021
| Name | Title | Pay | Year Born |
| Nadim Ahmed | President, Chief Executive Officer & Director | 1.17M | 1968 |
| Patrick A. Baeuerle | Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board | 763,734 | 1958 |
| Mary Kay Fenton | Chief Financial Officer | 768,257 | 1964 |
| Jeffrey Jones | Chief Medical Officer | 801,783 | 1971 |
| Corinne Savill | Chief Business Officer | 0 | 1959 |
| Jennifer Michaelson | Chief Scientific Officer | 0 | 1967 |
| Steve Andre | Chief Human Resources Officer | 0 | N/A |
| Rose Weldon | Senior Vice President of Corporate Affairs | 0 | N/A |
| Nicholas Smith | Head of Investor Relations | 0 | N/A |
| Jacquelyn L. Sumer | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | 0 | 1978 |
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.